메뉴 건너뛰기




Volumn 10, Issue 4, 2011, Pages 291-293

Ascorbic acid for treatment in CMT1A: What's next?

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; PERIPHERAL MYELIN PROTEIN 22; PLACEBO;

EID: 79952735251     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70042-4     Document Type: Letter
Times cited : (9)

References (18)
  • 2
    • 1942422646 scopus 로고    scopus 로고
    • Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease
    • Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004, 10:396-401.
    • (2004) Nat Med , vol.10 , pp. 396-401
    • Passage, E.1    Norreel, J.C.2    Noack-Fraissignes, P.3
  • 3
    • 71049172916 scopus 로고    scopus 로고
    • Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial
    • Verhamme C, de Haan RJ, Vermeulen M, et al. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med 2009, 7:70.
    • (2009) BMC Med , vol.7 , pp. 70
    • Verhamme, C.1    de Haan, R.J.2    Vermeulen, M.3
  • 4
    • 65549159213 scopus 로고    scopus 로고
    • Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial
    • Burns J, Ouvrier RA, Yiu EM, et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009, 8:537-544.
    • (2009) Lancet Neurol , vol.8 , pp. 537-544
    • Burns, J.1    Ouvrier, R.A.2    Yiu, E.M.3
  • 5
    • 72149100190 scopus 로고    scopus 로고
    • Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial
    • Micallef J, Attarian S, Dubourg O, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2009, 8:1103-1110.
    • (2009) Lancet Neurol , vol.8 , pp. 1103-1110
    • Micallef, J.1    Attarian, S.2    Dubourg, O.3
  • 6
    • 79952736703 scopus 로고    scopus 로고
    • Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial
    • for the CMT-TRIAAL and CMT-TRAUK groups, published online March 9.
    • Pareyson D, Reilly MM, Schenone A, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011, for the CMT-TRIAAL and CMT-TRAUK groups, published online March 9. 10.1016/S1474-4422(11)70025-4.
    • (2011) Lancet Neurol
    • Pareyson, D.1    Reilly, M.M.2    Schenone, A.3
  • 7
    • 16844381836 scopus 로고    scopus 로고
    • Reliability and validity of the CMT neuropathy score as a measure of disability
    • Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005, 64:1209-1214.
    • (2005) Neurology , vol.64 , pp. 1209-1214
    • Shy, M.E.1    Blake, J.2    Krajewski, K.3
  • 8
    • 39749139561 scopus 로고    scopus 로고
    • Neuropathy progression in Charcot-Marie-Tooth disease type 1A
    • Shy ME, Chen L, Swan ER, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008, 70:378-383.
    • (2008) Neurology , vol.70 , pp. 378-383
    • Shy, M.E.1    Chen, L.2    Swan, E.R.3
  • 9
    • 71049153213 scopus 로고    scopus 로고
    • The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study
    • Verhamme C, van Schaik IN, Koelman JH, et al. The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain 2009, 132:3252-3262.
    • (2009) Brain , vol.132 , pp. 3252-3262
    • Verhamme, C.1    van Schaik, I.N.2    Koelman, J.H.3
  • 10
    • 0027420097 scopus 로고
    • OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction
    • Tugwell P, Boers M OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. J Rheumatol 1993, 20:528-530.
    • (1993) J Rheumatol , vol.20 , pp. 528-530
    • Tugwell, P.1    Boers, M.2
  • 11
    • 78650170260 scopus 로고    scopus 로고
    • 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT)
    • Reilly MM, Shy ME, Muntoni F, Pareyson D 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscul Disord 2010, 20:839-846.
    • (2010) Neuromuscul Disord , vol.20 , pp. 839-846
    • Reilly, M.M.1    Shy, M.E.2    Muntoni, F.3    Pareyson, D.4
  • 12
    • 72449140657 scopus 로고    scopus 로고
    • Diagnosis and new treatments in genetic neuropathies
    • Reilly MM, Shy ME Diagnosis and new treatments in genetic neuropathies. J Neurol Neurosurg Psychiatry 2009, 80:1304-1313.
    • (2009) J Neurol Neurosurg Psychiatry , vol.80 , pp. 1304-1313
    • Reilly, M.M.1    Shy, M.E.2
  • 13
    • 0036788455 scopus 로고    scopus 로고
    • PMP22 overexpression causes dysmyelination in mice
    • Robaglia-Schlupp A, Pizant J, Norreel JC, et al. PMP22 overexpression causes dysmyelination in mice. Brain 2002, 125:2213-2221.
    • (2002) Brain , vol.125 , pp. 2213-2221
    • Robaglia-Schlupp, A.1    Pizant, J.2    Norreel, J.C.3
  • 14
    • 72649095062 scopus 로고    scopus 로고
    • Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A
    • Saporta MA, Katona I, Lewis RA, et al. Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A. Brain 2009, 132:3263-3273.
    • (2009) Brain , vol.132 , pp. 3263-3273
    • Saporta, M.A.1    Katona, I.2    Lewis, R.A.3
  • 15
    • 0034255676 scopus 로고    scopus 로고
    • Clinicoelectrophysiological correlation of extensor digitorum brevis muscle atrophy in children with Charcot-Marie-Tooth disease 1A duplication
    • Berciano J, Garcia J, Calleja J, Combarros O Clinicoelectrophysiological correlation of extensor digitorum brevis muscle atrophy in children with Charcot-Marie-Tooth disease 1A duplication. Neuromuscul Disord 2000, 10:419-424.
    • (2000) Neuromuscul Disord , vol.10 , pp. 419-424
    • Berciano, J.1    Garcia, J.2    Calleja, J.3    Combarros, O.4
  • 16
    • 0028800889 scopus 로고
    • Charcot-Marie-Tooth disease type 1A: morphological phenotype of the 17p duplication versus PMP22 point mutations
    • Gabreëls-Festen AA, Bolhuis PA, Hoogendijk JE, et al. Charcot-Marie-Tooth disease type 1A: morphological phenotype of the 17p duplication versus PMP22 point mutations. Acta Neuropathol 1995, 90:645-649.
    • (1995) Acta Neuropathol , vol.90 , pp. 645-649
    • Gabreëls-Festen, A.A.1    Bolhuis, P.A.2    Hoogendijk, J.E.3
  • 17
    • 41149124406 scopus 로고    scopus 로고
    • Lithium delays progression of amyotrophic lateral sclerosis
    • Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Nat Acad Sci USA 2008, 105:2052-2057.
    • (2008) Proc Nat Acad Sci USA , vol.105 , pp. 2052-2057
    • Fornai, F.1    Longone, P.2    Cafaro, L.3
  • 18
    • 79952739185 scopus 로고    scopus 로고
    • Lessons learned from Lithium trials in ALS
    • Miller RG, Katz J, Moore D Lessons learned from Lithium trials in ALS. Amyotroph Lateral Scler 2010, 11(suppl 1):63-71.
    • (2010) Amyotroph Lateral Scler , vol.11 , Issue.SUPPL. 1 , pp. 63-71
    • Miller, R.G.1    Katz, J.2    Moore, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.